List of Excipients in Branded Drug METFORMIN HYDROCHLORIDE ORAL SOLUTION

« Back to Dashboard

Generic Drugs Containing METFORMIN HYDROCHLORIDE ORAL SOLUTION

Company	Ingredient	NDC	Excipient
MICRO LABS LIMITED	metformin hydrochloride	42571-360	BENZOIC ACID
MICRO LABS LIMITED	metformin hydrochloride	42571-360	HYDROCHLORIC ACID
MICRO LABS LIMITED	metformin hydrochloride	42571-360	POTASSIUM BICARBONATE
MICRO LABS LIMITED	metformin hydrochloride	42571-360	SUCRALOSE
MICRO LABS LIMITED	metformin hydrochloride	42571-360	WATER
MICRO LABS LIMITED	metformin hydrochloride	42571-360	XANTHAN GUM

What are the Most Frequently-Used Excipients in METFORMIN HYDROCHLORIDE ORAL SOLUTION?

# Of NDCs	Excipient
4	BENZOIC ACID
4	HYDROCHLORIC ACID
4	POTASSIUM BICARBONATE
4	SUCRALOSE
4	WATER
4	XANTHAN GUM

Metformin Hydrochloride Oral Solution: Excipient Strategy, Patent Position, and Commercial Opportunities

Last updated: September 24, 2026

Metformin hydrochloride oral solution is a differentiated dosage form for patients who cannot swallow tablets, including children, older adults, patients with dysphagia, and individuals using enteral feeding tubes. The core active ingredient is old and largely exposed to generic competition, so commercial value depends on formulation execution rather than molecule-level exclusivity. The highest-value formulation priorities are taste masking, dose-measurement accuracy, microbial control, chemical stability, and a cost structure that supports broad payer access.

What is the FDA status of metformin hydrochloride oral solution?

The FDA-approved reference product is Riomet, a metformin hydrochloride oral solution supplied at 500 mg/5 mL, equivalent to 100 mg/mL of metformin hydrochloride. The product is approved for glycemic control in adults and pediatric patients at least 10 years old with type 2 diabetes mellitus, together with diet and exercise.[1]

Attribute	Riomet oral solution
Active ingredient	Metformin hydrochloride
Strength	500 mg/5 mL
Concentration	100 mg/mL
Dosage form	Oral solution
Route	Oral
FDA indication	Type 2 diabetes mellitus
Pediatric use	Approved for patients aged 10 years and older
Reference product sponsor	Sun Pharmaceutical Industries, Inc.
Regulatory pathway	505(b)(2) or product-specific NDA history, depending on the applicant and product
Primary commercial barrier	Taste, dosing convenience, and access rather than API exclusivity

The product labeling directs administration with meals and gradual dose titration to reduce gastrointestinal adverse effects. The maximum recommended daily dose for adults is generally 2,550 mg, although many patients receive lower maintenance doses.[1]

At 100 mg/mL, a 500 mg dose requires 5 mL, a 1,000 mg dose requires 10 mL, and a 2,000 mg dose requires 20 mL. Volume becomes a material commercial issue at higher doses.

What excipients are used in metformin oral solution?

The key excipient functions are pH control, viscosity adjustment, taste masking, preservation, flavoring, and dose uniformity. Public product labeling identifies excipients used in the Riomet formulation, including purified water, sucralose, strawberry flavor, xanthan gum, methylparaben, and propylparaben.[1]

Excipient function	Common candidate	Commercial purpose	Principal risk
Vehicle	Purified water	Dissolves metformin hydrochloride and supports low-cost manufacturing	Microbial growth and packaging compatibility
Sweetener	Sucralose	Masks metformin bitterness	Aftertaste and taste fatigue
Flavor	Strawberry or berry flavor	Improves acceptability, especially in pediatric patients	Flavor instability and patient preference variability
Viscosity modifier	Xanthan gum	Improves mouthfeel and reduces rapid runoff during dosing	Stringiness, fill-weight variation, and mixing challenges
Preservative	Methylparaben and propylparaben	Controls microbial contamination after opening	Regulatory limits, preservative effectiveness, and sensitivity concerns
pH adjustment	Hydrochloric acid, sodium hydroxide, citrate, or phosphate systems	Controls stability, taste, and preservative performance	Buffer capacity, precipitation, and container interaction

The formulation target should not be to maximize sweetness. Metformin has a strong bitter taste, and excessive sweetener can create an unpleasant delayed aftertaste. A better strategy combines a high-intensity sweetener with flavor modulation, moderate viscosity, and controlled pH.

How should an excipient strategy be designed for metformin hydrochloride oral solution?

The most commercially defensible excipient strategy has five elements.

1. Use a low-excipient, aqueous platform

Metformin hydrochloride is highly water soluble, which supports a conventional aqueous solution rather than a suspension or complex delivery system. A solution avoids sedimentation, shaking requirements, and dose nonuniformity associated with suspensions.

The formulation should use the minimum excipient load required to achieve:

• acceptable taste;
• preservative effectiveness;
• chemical and microbiological stability;
• consistent viscosity;
• compatibility with the dosing device.

A low-excipient formula reduces cost and simplifies regulatory justification.

2. Optimize taste masking around the actual dose volume

Taste testing should assess the dose volume patients will experience, not only a diluted laboratory sample. A 5 mL pediatric dose creates a different sensory profile from a 15 mL or 20 mL adult dose.

The development program should compare:

• sucralose alone;
• sucralose combined with a polyol such as sorbitol;
• acesulfame potassium or other high-intensity sweeteners;
• berry, grape, cherry, and citrus flavors;
• bitterness blockers or ion-exchange approaches;
• mildly viscous versus low-viscosity formulations.

Polyols may improve mouthfeel but can introduce gastrointestinal tolerability concerns. That issue is relevant because metformin itself commonly causes gastrointestinal symptoms. A formulation that adds substantial sorbitol or mannitol may create an avoidable tolerability problem.

3. Control viscosity without impairing dosing

Xanthan gum is attractive because it is widely used, inexpensive, and compatible with aqueous systems. Excessive viscosity, however, can cause:

• inaccurate dosing from oral syringes;
• residual product remaining in the bottle;
• delayed draining from the dosing device;
• poor acceptability in children;
• fill-volume and line-clearance problems during manufacturing.

A target viscosity should be established against the selected dosing device. The product should be tested with oral syringes, dosing cups, and feeding tubes if tube administration is commercially contemplated.

4. Design preservation around multidose use

A multidose oral solution is exposed repeatedly to air, dosing devices, and household handling. Preservative effectiveness testing should evaluate the marketed bottle, closure, and dosing accessory as an integrated system.

Parabens provide a familiar preservation platform, but a reformulator may consider alternatives such as potassium sorbate, sodium benzoate, or benzoic acid where compatible with pH and taste. Any preservative change requires assessment of:

• preservative effectiveness;
• pH dependence;
• container adsorption;
• extractables and leachables;
• pediatric exposure;
• regulatory acceptability in target countries.

Unit-dose packaging can reduce preservative requirements but usually increases packaging cost and distribution complexity.

5. Build the formulation around the package

Packaging is a core part of the product opportunity. Suitable options include:

• amber polyethylene terephthalate or high-density polyethylene bottles;
• child-resistant closures;
• integrated oral-syringe adapters;
• unit-dose sachets or stick packs;
• blow-fill-seal containers;
• low-volume bottles for pediatric use.

The package should minimize dosing loss and make it difficult to confuse milligrams with milliliters. A 100 mg/mL product can create medication errors when caregivers interpret "500 mg" as "5 mL" without clear labeling.

What formulation patents could protect metformin oral solution?

Metformin hydrochloride itself has no meaningful new-molecule patent barrier in the United States. The commercial opportunity is therefore based on formulation, device, manufacturing, or use claims.

Potentially protectable subject matter includes:

Patent category	Potential claim focus	Relative strength
Taste-masked solution	Specific sweetener-flavor system or bitterness blocker	Moderate if clinically or analytically differentiated
Preservative system	Preservative combination at defined pH and concentration	Low to moderate
Dosing device	Bottle and oral syringe system that improves dose accuracy	Moderate
Enteral administration	Tube-compatible formulation with reduced clogging or adsorption	Moderate
Pediatric formulation	Taste, dose, and age-specific administration method	Moderate, but obviousness risk is significant
Manufacturing method	Mixing sequence, deaeration, or filtration process	Low unless it solves a documented technical problem
Stability	Defined pH, excipient, and container combination extending shelf life	Moderate if supported by unexpected data
New indication	Specific population or administration regimen	Usually narrow and vulnerable to validity challenges

A broad claim covering "metformin hydrochloride in an aqueous solution with a sweetener and flavor" would likely face significant novelty and obviousness pressure because oral solutions and taste-masking techniques are established technologies. Stronger protection would require comparative data showing an unexpected result, such as materially improved palatability, reduced dosing error, enhanced stability, or superior compatibility with enteral tubes.

What is the Orange Book and exclusivity position for metformin oral solution?

Metformin has no remaining meaningful compound exclusivity. Any current protection would be product-specific and would need to be verified against the FDA Orange Book and the relevant approved-label history.[2]

Exclusivity type	Commercial assessment
New chemical entity exclusivity	Expired
Basic metformin composition patent	Expired
Tablet and extended-release technology	Broadly genericized
Oral-solution exclusivity	Product-specific; must be checked by NDA and listing
Pediatric exclusivity	May attach only if granted for a qualifying product and period
Orphan exclusivity	Not applicable to ordinary type 2 diabetes use
Formulation patents	Potentially relevant only if listed and unexpired
Method-of-use patents	Narrow relevance because metformin has mature diabetes indications

For a generic oral solution, the strategic question is not whether metformin is patent-free in the abstract. The question is whether an applicant can obtain approval without infringing any unexpired formulation, device, or method-of-use patent listed for the reference product. A Paragraph IV certification may be relevant if an unexpired listed patent remains. If no relevant listed patent exists, the applicant may rely on Paragraph III or a section viii statement, depending on the approved labeling and patent record.[2,3]

When does metformin oral solution lose exclusivity?

The active ingredient has already lost primary patent exclusivity. The relevant commercial timing is therefore determined by:

1. the remaining patent and exclusivity listings for the reference oral solution;
2. the timing of ANDA or 505(b)(2) approval;
3. manufacturing readiness;
4. retail and payer access;
5. the ability to secure pharmacy stocking.

Generic entry could occur through an ANDA if the applicant can demonstrate pharmaceutical equivalence, bioequivalence where required, and compliance with applicable requirements. A 505(b)(2) pathway may be more suitable where the applicant introduces a materially different formulation, dosing device, preservative system, concentration, or administration claim.

What generic entry risks exist for metformin oral solution?

The main risks are commercial and regulatory rather than compound-patent risks.

Regulatory risks

A solution must demonstrate appropriate quality attributes, including:

• assay and content uniformity;
• pH;
• preservative content;
• microbial limits;
• preservative effectiveness;
• viscosity;
• stability;
• container-closure integrity;
• dose delivery accuracy.

If the proposed product differs materially in excipients, concentration, flavor, or dosing device, the regulatory pathway may become more complex. A 505(b)(2) product could support differentiation but may require additional clinical or bridging evidence.

Commercial risks

The tablet market is dominated by low-cost generic metformin. Many patients can use immediate-release or extended-release tablets at a fraction of the cost of an oral solution. The solution therefore targets a narrower population with a specific administration need.

The product must justify its premium through:

• improved swallowing access;
• pediatric acceptability;
• accurate dosing;
• tube administration;
• reduced caregiver burden;
• reliable pharmacy supply.

Litigation risks

Because metformin is mature, litigation risk is likely to center on narrow formulation or device patents rather than basic active-ingredient claims. A Paragraph IV challenge could be attractive if the reference product has a listed patent with a commercially meaningful remaining term. The expected value of litigation would depend on the size of the oral-solution market, the strength of the asserted claims, and whether a first applicant can obtain 180-day generic exclusivity.

Which companies are competing in metformin oral solution?

Sun Pharmaceutical Industries is associated with Riomet, the principal U.S. branded oral solution reference product. Competition also comes from:

• compounded metformin solutions prepared by pharmacies;
• overseas oral-liquid products;
• hospital and institutional formulations;
• immediate-release tablets that can sometimes be administered through feeding tubes under institution-specific protocols;
• metformin extended-release products, which compete for overall diabetes prescriptions but are not direct substitutes for a liquid dosage form.

A new entrant would compete less on molecule and more on product design. Differentiation could include sugar-free formulation, alcohol-free formulation, improved taste, unit-dose packaging, tube compatibility, or a lower-cost generic presentation.

What commercial opportunities exist for metformin oral solution?

Pediatric diabetes

The FDA-approved pediatric population begins at age 10 for type 2 diabetes. Pediatric packaging, palatable flavor, and an oral syringe can support adherence and caregiver confidence. The addressable population is smaller than the adult market, but pediatric patients are more likely to need a liquid dosage form.

Dysphagia and geriatric care

Older adults and patients with neurologic disease may have difficulty swallowing tablets. A liquid can support home care, skilled nursing, and assisted-living use. The product should be evaluated for dose accuracy when administered by caregivers with different levels of training.

Enteral feeding

Tube administration is a meaningful opportunity, but it requires direct testing. The formulation should be evaluated for:

• tube size;
• adsorption to tubing;
• clogging;
• required flush volume;
• compatibility with enteral nutrition;
• recovery of the administered dose.

A tube-compatible label claim could create stronger differentiation than flavor alone.

Global markets

Liquid diabetes medicines may have greater relevance in markets with lower tablet adherence, limited access to swallowing aids, or higher pediatric use. Excipient selection must account for regional restrictions on preservatives, flavors, sweeteners, and allergens.

Institutional and specialty channels

Hospitals, long-term-care facilities, pediatric endocrinology practices, and home-health providers can support targeted distribution. A manufacturer may obtain better market access by offering calibrated oral syringes and staff-oriented dosing instructions rather than relying solely on retail pharmacy placement.

How does metformin oral solution compare with tablets and suspensions?

Product type	Main advantage	Main limitation	Commercial position
Immediate-release tablet	Lowest cost and established use	Swallowing burden and gastrointestinal effects	Dominant generic segment
Extended-release tablet	Lower dosing frequency and improved tolerability for some patients	Cannot always be crushed or administered through tubes	Strong substitute
Oral solution	Flexible dosing and swallowing access	Taste, volume, stability, and higher cost	Niche but defensible
Oral suspension	Can support insoluble or modified-release systems	Requires shaking and creates dose-uniformity risk	Less attractive where metformin readily dissolves
Compounded liquid	Flexible concentration and local availability	Variable quality, availability, and stability	Substitute in specialty settings

A solution is technically preferable to a suspension because metformin hydrochloride is highly soluble. The commercial challenge is that the simplest technical formulation is also easier for competitors to reproduce.

How strong is the patent estate for metformin oral solution?

The patent estate is weak at the molecule level and potentially moderate at the product level. A defensible formulation patent would need narrow, data-supported claims that solve a specific problem. The most credible claim areas are:

• measurable taste improvement;
• improved oral-syringe dose recovery;
• stable preservative performance over the labeled shelf life;
• reduced tube adsorption or clogging;
• packaging that reduces dosing error;
• a defined excipient system with unexpected stability or palatability results.

A product relying only on conventional water, sweetener, flavor, viscosity modifier, and preservative is unlikely to support broad, durable exclusivity without strong comparative data.

Key Takeaways

• Metformin hydrochloride oral solution is a formulation-led opportunity, not a molecule-exclusivity opportunity.
• Riomet establishes a U.S. reference product at 500 mg/5 mL, or 100 mg/mL.
• The critical excipients are sweeteners, flavors, viscosity modifiers, preservatives, pH adjusters, and the dosing-device system.
• Taste masking and dose accuracy are the highest-priority development issues.
• A solution is generally preferable to a suspension because metformin hydrochloride is highly water soluble.
• The strongest commercial niches are pediatric use, dysphagia, geriatric care, enteral feeding, and institutional administration.
• Broad formulation patents are likely vulnerable unless supported by unexpected stability, palatability, or delivery data.
• Generic entry risk is substantial because metformin has no meaningful new-chemical-entity barrier.
• A differentiated 505(b)(2) product may offer greater commercial flexibility than a conventional generic, but it may require additional regulatory support.
• Packaging, oral-syringe integration, and tube compatibility can create more practical value than incremental changes to flavor alone.

FAQs

Is metformin oral solution better than metformin tablets?

It is better for patients who cannot swallow tablets or need flexible liquid dosing. Tablets remain more economical and convenient for most adults.

Can metformin oral solution be administered through a feeding tube?

Administration should be supported by product-specific compatibility data. Tube size, flushing, adsorption, and clogging must be evaluated before making a commercial tube-use claim.

Is metformin oral solution suitable for children?

The FDA-approved Riomet labeling includes pediatric patients aged 10 years and older with type 2 diabetes. Pediatric development should focus on taste, dosing-device accuracy, and caregiver instructions.[1]

What is the most valuable excipient innovation for metformin liquid?

A validated taste-masking system that improves acceptance without adding gastrointestinally active polyols or excessive viscosity has the strongest commercial relevance.

Can a company patent a new metformin oral solution?

Yes, but protection would likely need to focus on a specific formulation, dosing device, administration method, packaging system, or manufacturing process. Broad claims covering a conventional aqueous metformin solution would face substantial validity risk.

References

1. Sun Pharmaceutical Industries, Inc. (n.d.). Riomet (metformin hydrochloride) oral solution: Prescribing information. U.S. Food and Drug Administration.

2. U.S. Food and Drug Administration. (n.d.). Approved drug products with therapeutic equivalence evaluations: Orange Book. https://www.fda.gov/drugsatfda

3. U.S. Food and Drug Administration. (n.d.). ANDA submissions: Content and format of an abbreviated new drug application. https://www.fda.gov/drugs/guidance-compliance-regulatory-information/guidances-drugs